

Pubblicazioni

1. E.M. Pogliani, **F. Arienti**, S. Magni, G. Corneo: L'impiego delle immunoglobuline endovena (IVIG) nell'anemia emolitica autoimmune (AIHA). Incontro nella terra dei Medici. Impiego clinico delle immunoglobuline endovena: presente e futuro. Ed. P. Rossi Ferrini. 87-93, 1988.
2. E.M. Pogliani, **F. Arienti**, G. Corneo: Intravenous infusion of gammaglobulin in adults with chronic refractory immune thrombocytopenic purpura. *Blood*, 74: 886, 1989.
3. G. Parmiani, L. Rivoltini, C. Gambacorti-Passerini, **F. Arienti**, L. Borin, E.M. Pogliani, G.M. Corneo: Purging di midollo osseo con cellule LAK. 2° Simposio Nazionale sulla Criopreservazione delle Cellule Emopoietiche., 130-135, 1990.
4. L. Rivoltini, G. Cattoretti, **F. Arienti**, A. Mastroianni, C. Melani, M.P. Colombo and G. Parmiani: The high lysability by LAKs of colon carcinoma cells resistant to Doxorubicin is associated with a high expression of ICAM1, LFA3, NCA and a less-differentiated phenotype. *Int. J. Cancer*, 47: 746-754, 1991.
5. G. Parmiani, A. Anichini, L. Rivoltini, **F. Arienti**, F. Belli, N. Cascinelli: Immunotherapy of cancer with IL-2 and lymphocytes: possible reasons for the variable clinical response. *Frontiers in autoimmune diseases and cancer immunotherapy*. Edi-Ermes, Milano; 307-323, 1991.
6. S. Spinazze', S. Viviani, P. Bidoli, F. Rovelli, **F. Arienti**, L. Rivoltini, and G. Parmiani: Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythm of cortisol and beta-endorphin in advanced small cell lung cancer patients. *Tumori*, 77: 496-499, 1991.
7. G. Parmiani, G. Cefalo, L. Rivoltini, **F. Arienti**, M. Gasparini, F. Fossati-Bellani: Immunoterapia con interleukina-2 ricombinante e linfociti (LAK/TIL) in pazienti affetti da tumori dell'eta' pediatrica. *Riv. Infettiv. Ped.*, 6: 33-44, 1991.
8. G. Parmiani, **F. Arienti**: Antigeni oncofetali. *Enciclopedia Medica Italiana*; 3: 5526-5531, 1991.
9. L. Rivoltini, **F. Arienti**, A. Orazi, G. Cefalo, M. Gasparini, C. Gambacorti-Passerini, F. Fossati-Bellani, and G. Parmiani: Phenotypic and functional analysis of lymphocytes infiltrating pediatric tumors, with a characterization of the tumor phenotype. *Cancer Immunol. Immunother.*, 34: 241-251, 1992.
10. **F. Arienti**, C. Gambacorti-Passerini, L. Borin, L. Rivoltini, A. Orazi, E.M. Pogliani, G. Corneo, G. Parmiani: Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug-resistance and in the expression of adhesion molecules. *Ann. Oncol.*, 3:155-162, 1992.
11. G. Parmiani, **F. Arienti**, L. Rivoltini, F. Belli and N. Cascinelli: Human tumour infiltrating lymphocytes in the treatment of cancer. *Forum.*, 2: 412-419, 1992.

12. G. Parmiani, **F. Arienti**: Il punto sui BRM in clinica: le interleuchine. XIV corso di aggiornamento in oncologia medica. Corso per medici. O.C.T. Ed. Trieste, 477-482, 1992.
13. A. Silvani, L. Rivoltini, **F. Arienti**, G. Parmiani, A. Boiardi: Immunoterapia attiva con A-LAK nei tumori gliali maligni. Neuro-oncologia: attualità diagnostico terapeutiche dei più frequenti tumori cerebrali maligni. Compagnia della Comunicazione Ed.; 237-244, 1992.
14. L. Rivoltini, P.A. Ruffini, **F. Arienti**, A. Silvani, A. Boiardi, G. Parmiani: Immunoterapia dei tumori: attualità nelle neoplasie cerebrali. Neuro-oncologia: attualità diagnostico terapeutiche dei più frequenti tumori cerebrali maligni. Compagnia della Comunicazione - Ed.; 89-104, 1992.
15. L. Rivoltini, G. Cattoretti, **F. Arienti**, A. Mastroianni and G. Parmiani: CEA and NCA expressed by colon carcinoma cells affect their interaction with and lysability by activated lymphocytes. *Int. J. Biol. Markers*; 3: 143-147, 1992.
16. F. Belli, **F. Arienti**, L. Rivoltini, M. Santinami, L. Mascheroni, A. Prada, M. Ammatuna, E. Marchesi, G. Parmiani, N. Cascinelli, M. Vaglini: Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extra-corporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study. *Melanoma Res*; 2: 263-271, 1992.
17. C. Gambacorti-Passerini, F. Grignani, **F. Arienti**, P.P. Pandolfi, P.G. Pelicci and G. Parmiani: Human CD4 lymphocytes specifically recognize a peptide representing the fusion of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. *Blood*; 5: 1369-1375, 1993.
18. A. Caraceni, C. Martini, F. Belli, L. Mascheroni, L. Rivoltini, **F. Arienti**, N. Cascinelli: Neuropsychological and neurophysiological assessment of the central effects of interleukin 2 administration. *Eur. J. Cancer*; 9: 1266-1269, 1993.
19. **F. Arienti**, F. Belli, L. Rivoltini, C. Gambacorti-Passerini, L. Furlan, L. Mascheroni, A. Prada, M. Rizzi, E. Marchesi, M. Vaglini, G. Parmiani, N. Cascinelli. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor infiltrating lymphocytes (TIL) selected in vitro with low doses of IL-2. *Cancer Immunol. Immunother.*; 36: 315-322. 1993.
20. G. Parmiani, **F. Arienti**, F. Belli, M. Santinami, M. Vaglini, and N. Cascinelli. Adoptive immunotherapy of melanoma with interleukin-2 and lymphocytes. *Molecular oncology and clinical applications*. A. Cittadini et al. (eds). 243-252. 1993.
21. S. Viviani, PM. Salvini, P. Bidoli, E. Camerini, S. Spinazze', **F. Arienti**, L. Rivoltini, V. Motta. Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer. *Int. J. Biol. Markers*; 8, 1: 21-24, 1993.
22. C. Melani, C. Chiodoni, **F. Arienti**, C. Maccalli, J. Sule'-Susso, A. Anichini, MP. Colombo, G. Parmiani. Cytokine gene transduction in tumor cells: IL-2 or IL-4 gene transfer in human melanoma cells. *Nat. Immun.*; 13: 76-84, 1994.
23. L. Rivoltini, **F. Arienti**, F. Belli, N. Cascinelli, G. Parmiani. Adoptive immunotherapy of human melanoma with IL-2 and lymphocytes: results and perspective. In "Cytokine induced tumor immunogenicity: from exogenous

molecules to gene therapy", G. Forni, R. Foa', A. Santoni, L. Frati, eds, 365-383, 1994.

24. C. Botti, A. Bogni, E. Seregini, **F. Arienti**, S. Massaron, and E. Bombardieri. Diagnostica sierologica del carcinoma renale. *Acta Oncologica* 15, 353-359, 1994.
25. N. Cascinelli, R. Foa', G. Parmiani, **F. Arienti**, F. Belli, M.G. Bernengo, C. Clemente, M.P. Colombo, A. Guarini, M.T. Illeni, L. Mascheroni, C. Melani, A. Prada, J. Sule'-Susso. Clinical protocol: active immunization of metastatic melanoma patients with interleukin-4 transduced allogeneic melanoma cells. A phase I-II study. *Hum. Gene Ther.*; 5: 1059-1064, 1994.
26. **F. Arienti**, J. Sule'-Susso, C. Melani, C. Maccalli, F. Belli, M.T. Illeni, A. Anichini, N. Cascinelli, M.P. Colombo, G. Parmiani. IL-2 gene -transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. *Hum. Gene Ther.*; 5: 1139-1150, 1994.
27. M. Vaglini, F. Belli, M. Santinami, **F. Arienti**, G. Parmiani, L. Persiani, N. Santoro, M.G. Inglese, F. D'Elia, and N. Cascinelli. Isolation perfusion in extracorporeal circulation with Interleukin-2 and lymphokine activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma. *Ann. Surg. Oncol.*; 2(1): 61-70, 1995.
28. J. Sule'-Susso, **F. Arienti**, F. Belli, C. Melani, L. Mascheroni, M.P. Colombo, N. Cascinelli, G. Parmiani. Vaccination of melanoma patients with interleukin-2 transduced, allogeneic melanoma cells: an overview. In "The Internet Book of Gene Therapy. Cancer Therapeutics", RE Sobol and KJ Scanlon eds, Appleton & Lange, Stamford USA, pp: 189-194, 1995.
29. S. Canevari, G. Stoter, **F. Arienti**, G. Bolis, M.I. Colnaghi, E. M. Di Re, A.M.M. Eggermont, S.H. Goey, J.W. Gratama, C.H.J. Lamers, M.A. Nooy, G. Parmiani, F. Raspagliesi, F. Ravagnani, G. Scarfone, J.B. Trimpos, S.O. Warnaar, and R.L.H. Bolhuis. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. *J. Natl. Cancer Inst.*, 87, 19: 1463-1469, 1995.
30. S. Salvi, F. Segalla, S. Rao, **F. Arienti**, M. Sartori, G. Bratina, E. Caronni, A. Anichini, C. Clemente, G. Parmiani, M.L. Sensi. Overexpression of the T-cell receptor beta-chain variable-region TCRBV14 in HLA-A2-matched primary human melanomas. *Cancer Res.*, 55: 3374-3379, 1995.
31. J. Sule'-Susso, **F. Arienti**, C. Melani, M.P. Colombo, and G. Parmiani. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. *Eur. J. Immunol.* 25: 2737-2742, 1995.
32. C. Melani, J. Sule'-Susso, **F. Arienti**, C. Maccalli, F. Passerini, M.P. Colombo and G. Parmiani. A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. *Hum. Gene Ther.* 6: 1427-1436, 1995.
33. M. Marchand, P. Weynants, G. Parmiani, **F. Arienti**, F. Belli, N. Cascinelli, E. Rankin, A. Bourlond, R. Vanwijck, Y. Humblet, J.-L. Canon, C. Laurent, J.-M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jaeger, F. Brasseur, P. Coulie and T. Boon. Tumor regression responses in HLA-A1 melanoma patients treated with a peptide encoded by gene MAGE-3. *Int. J. Cancer* 63; 883-885, 1995.

34. F. Brasseur, D. Rimoldi, D. Lienard, B. Lethe, S. Carrel, **F. Arienti**, L. Suter, R. Vanwijck, A. Boulond, Y. Humblet, A. Vacca, M. Conese, T. Lahaye, G. Degiovanni, R. Deraemaeker, M. Beauduin, X. Sastre, E. Salamon, B. Dreno, A. Knuth, C. Chevreau, S. Suci, J.-M. Lachapelle, P. Pouillart, G. Parmiani, F. Lejeune, J.-C. Cerottini, T. Boon and M. Marchand. Expression of MAGE genes in primary and metastatic cutaneous melanoma. *Int. J. Cancer* 63; 375-380, 1995.
35. L. Rivoltini, D. J. Loftus, K. Barracchini, **F. Arienti**, A. Mazzocchi, W. E. Biddison, M. L. Salgaller, E. Appella, G. Parmiani, and F. Marincola. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. *J. Immunol.*, 156; 3882-3891, 1996.
36. **F. Arienti**, J. Sule'-Suso, F. Belli, L. Mascheroni, L. Rivoltini, C. Melani, M. Maio, N. Cascinelli, M.P. Colombo and G. Parmiani. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. *Hum. Gene Ther.* 7: 1955-1963, 1996.
37. G. Parmiani, **F. Arienti**, F. Belli, L. Mascheroni, N. Cascinelli. Potenzialita' della terapia genica dei tumori. XVI Corso di aggiornamento in Oncologia Medica. 351-357, 1996.
38. G. Parmiani, **F. Arienti**, J. Sule'-Suso, C. Melani, M.P. Colombo, V. Ramakrishna, F. Belli, L. Mascheroni, L. Rivoltini, N. Cascinelli. Cytokine-based gene therapy of human tumors. An overview. *Folia Biologica (Praha)* 42, 305-309, 1996.
39. MA. Player, KC. Barracchini, TB. Simonis, L. Rivoltini, **F. Arienti**, C. Castelli, A. Mazzocchi, F. Belli, G. Parmiani and FM. Marincola. Differences in frequency distribution of HLA-A2 subtypes between North American and Italian Caucasian Melanoma patients: relevance for epitope specific vaccination protocols. *J. Immunother.* 19, 357-363, 1996.
40. C. Botti, D.R.M. Negri, E. Seregini, V. Ramakrishna, **F. Arienti**, L. Maffioli, C. Lombardo, A. Boggi, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, E. Bombardieri. Comparison of three different methods for radiolabelling of human activated T lymphocytes. *Eur. J. Nucl. Med.* 24, 497-504, 1997.
41. F. Belli, **F. Arienti**, J. Sule'-Suso, C. Clemente, L. Mascheroni, A. Cattelan, C. Sanantonio, G.F. Gallino, C. Melani, S. Rao, M.P. Colombo, M. Maio, N. Cascinelli, G. Parmiani. Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. *Cancer Immunol. Immunother.* 44, 197-203, 1997.
42. G. Parmiani, M. P. Colombo, C. Melani, **F. Arienti**. Cytokine gene transduction in the immunotherapy of tumors. In "Advances in Pharmacology", Academic Press, NY. 259-307, 1997.
43. L. Rivoltini, D.J. Loftus, P. Squarcina, C. Castelli, F. Rini, **F. Arienti**, F. Belli, F.M. Marincola, C. Geisler, A. Borsatti, E. Appella, G. Parmiani. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. *Critical Rev. Immunol.* 18, 55-63, 1998.
44. D. J. Hicklin, Z. Wang, **F. Arienti**, L. Rivoltini, G. Parmiani, and S. Ferrone. β_2 -microglobulin mutations, HLA Class I loss, and tumor progression in melanoma. *J. Clin. Invest.* 12, 2720-2729, 1998.

45. Z. Wang, **F. Arienti**, G. Parmiani and S. Ferrone. Induction and functional characterization of $\beta_2\text{-}\mu$ free HLA Class I heavy chains expressed by $\beta_2\text{-}\mu$ -deficient cultured melanoma cells FO-1. *Eur. J. Immunol.* 28, 2817-2826, 1998.
46. M. Marchand, N. van Baren, P. Weynants, V. Brichard, B. Dreno, M.-H. Tessier, E. Rankin, G. Parmiani, **F. Arienti**, Y. Humblet, A. Bourlond, R. Vanwijck, D. Lienard, M. Beauduin, P.-Y. Dietrich, C. Traversari, J. Kerger, G. Masucci, E. Jager, J. De Greve, J. Atzpodien, F. Brasseur, P. G. Coulie, P. van der Bruggen and T. Boon. Tumor regression observed in metastatic melanoma of patients treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int. J. Cancer* 80, 219-230, 1999.
47. **F. Arienti**, F. Belli, F. Napolitano, J. Sule'-Suso, A. Mazzocchi, G. Gallino, A. Cattelan, C. Santantonio, L. Rivoltini, C. Melani, M.P. Colombo, N. Cascinelli, M. Maio and G. Parmiani. Vaccination of melanoma patients with IL-4 gene-transduced allogeneic melanoma cells. *Hum. Gene Ther.* 10, 2907-2916, 1999.
48. G. Parmiani, **F. Arienti**, C. Melani, F. Belli, G. Gallino and A. Mazzocchi. Gene therapy of melanoma. B. Nickoloff eds; Humana Press, 2000.
49. M. Maio, E. Fonsatti, E. Lamaj, M. Altomonte, I. Cattarossi, C. Santantonio, C. Melani, F. Belli, **F. Arienti**, M. P. Colombo, G. Parmiani. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. *Cancer Immunol. Immunother.* 51, 9-14, 2002.
50. F. Belli, A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, M. Carrabba, G. Scita, C. Santantonio, L. Pilla, G. Tragni, C. Lombardo, **F. Arienti**, A. Marchiano', F. Bertolini, A. Cova, E. Lamaj, L. Ascani, R. Camerini, M. Corsi, N. Cascinelli, P. K. Srivastava, J. J. Lewis and G. Parmiani. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein peptide-complex-96 (Oncophage): clinical and immunological findings. *J. Clin. Oncol.* 15, 4139-4140, 2002.
51. M. Rodolfo, R. Luksch, E. Stockert, Y. Chen, P. Collini, T. Ranzani, C. Lombardo, P. Dalerba, L. Rivoltini, **F. Arienti**, F. Fossati-Bellani, L. J. Old, G. Parmiani and C. Castelli. Antigen specific immunity in neuroblastoma patients: antibody and T cell recognition of NY-ESO-1 tumor antigen. *Cancer Res.* 15, 6948-6955, 2003
52. D. Tosi, R. Valenti, A. Cova, G. Sovena, V. Huber, L. Pilla, **F. Arienti**, F. Belardinelli, G. Parmiani and L. Rivoltini. Role of cross-talk between IFN- α -induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. *J. Immunology* 172: 5363-5370, 2004
53. T. Di Pucchio, L. Pilla, I. Capone, M. Ferrantini, E. Montefiore, F. Urbani, R. Patuzzo, E. Pennacchioli, M. Santinami, A. Cova, G. Sovena, **F. Arienti**, C. Lombardo, A. Lombardi, P. Caporaso, S. D'Atri, P. Marchetti, E. Bonmassar, G. Parmiani, F. Belardelli, L. Rivoltini. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN- α results in the activation of specific CD8+T cells and monocytes/dendritic cell-precursors. *Cancer Res.* 66: 4943-4951, 2006

54. L. Pilla, R. Patuzzo, L. Rivoltini, M. Maio, E. Pennacchioli, E. Lamaj, A. Maurichi, S. Massarut, A. Marchiano', C. Santantonio, D. Tosi, **F. Arienti**, A. Cova, G. Sovena, A. Piris, D. Nonaka, I. Bersani, A. Di Florio, PK. Srivastava, A. Hoos, M. Santinami, G. Parmiani. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon- α in metastatic melanoma patients. *Cancer Immunol Immunother* 55: 958-968, 2006
55. C. Casati, C. Camisaschi, F. Rini, **F. Arienti**, L. Rivoltini, F. Triebel, G. Parmiani and C. Castelli. Soluble Human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. *Cancer Res.* 66, 4450-4460, 2006
56. F. Ravagnani, P. Coluccia, P. Notti, **F. Arienti**, A. Bompadre, M. Avella, F. Bozzi, M. Barzano', M.G. Podda, A. Pupa, R. Luksch: Peripheral blood stem cell collection in pediatric patients. Feasibility of leukapheresis under anesthesia in uncompliant small children with solid tumors. *J Clin Apher* 21: 85-91, 2006
57. M. Daniotti, V. Vallacchi, L. Rivoltini, R. Patuzzo, M. Santinami, **F. Arienti**, M. A. Pierotti, G. Parmiani, M. Rodolfo: Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. *Int J Cancer* 120(11): 2439-44, 2007
58. C. Maccalli, V. Di Cristanziano, V. Fodale, D. Corsi, G. D'Agostino, V. Petrangeli, L. Laurenti, S. Guida, A. Mazzocchi, **F. Arienti**, M. P. Perrone, C. Castelli, L. Rivoltini, V. Zagonel, M. Tartaglia, G. Parmiani and F. Belardelli. Induction of Both CD8+ and CD4+ T-Cell Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1. *Clin Cancer Res* 14(22), 2008
59. A. De Filippo, R.J. Binder, C. Camisaschi, V. Beretta, **F. Arienti**, A. Villa, P. Della Mina, G. Parmiani, L. Rivoltini, C. Castelli. [Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses.](#) *J Immunol.* 181(9):6525-35, 2008
60. R. Mortarini, C. Vegetti, A. Molla, **F. Arienti**, F. Ravagnani, A. Maurichi, R. Patuzzo, M. Santinami and A. Anichini. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. *Clin Cancer Res* 15(12): 2009
61. A. Anichini, A. Molla, C. Vegetti, I. Bersani, R. Zappasodi, **F. Arienti**, F. Ravagnani, A. Maurichi, R. Patuzzo, M. Santinami, H. Pircher, M. Di Nicola, R. Mortarini,: Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma. *Cancer Res* 70: 8378-87, 2010
62. C. Camisaschi, A. De Filippo, V. Beretta, B. Vergani, A. Villa, E. Vergani, M. Santinami, A. D. Cabras, **F. Arienti**, F. Triebel, M. Rodolfo, L. Rivoltini, C. Castelli: Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. *J. Invest. Dermatol* 134: 1893-1902, 2014
63. F. Taverna, P. Coluccia, **F. Arienti**, A. Birolini, L. Terranova, A. Mazzocchi, F. Rini, L. Mariani, C. Melani, F. Ravagnani: Biological quality control for extracorporeal photochemotherapy: assessing mononuclear cell apoptosis levels in ECP bags of chronic GvHD patients. *J. Clin. Apher* 15, 2014
64. A. Necchi, R. Miceli, P. Pedrazzoli, P. Giannatempo, S. Secondino, M. Di Nicola, E. farè, D. Raggo, M. Magni, P. Matteucci, P. Longoni, M. Milanese, E. Paternò, F. Ravagnani, **F. Arienti**, N. Nicolai, R. Salvioni, C. Carlo-Stella, A. M. Gianni: Predictors of CD34+ mobilization and collection in adult men with

germ cell tumors: implications for the salvage treatment strategy. Clin. Genitourin Cancer 12; 196-202, 2014

65. V. Vallacchi, E. Vergani, C. Camisaschi, P. Deho, A. D. Cabras, M. Sensi, L. De Cecco, N. Bassani, F. Ambrogi, A. Carbone, F. Crippa, B. Vergani, P. Frati, **F. Arienti**, R. Patuzzo, A. Villa, E. Biganzoli, S. Canevari, M. Santinami, C. Castelli, L. Rivoltini, M. Rodolfo: Transcriptional profiles of sentinel nodes identify patients with poor outcome and reveal an association of CD30+ T lymphocytes with melanoma progression. Cancer Res 74; 130-140, 2014